Dayoub EJ, et al. - In this retrospective cohort study, the researchers sought to ascertain trends in use of the different P2Y₁₂ inhibitors in patients who underwent percutaneous coronary intervention (PCI) from 2008 to 2016 in a large cohort of commercially insured patients and differences in patient adherence and costs among the P2Y₁₂ inhibitors. They involved fifty-five thousand, three hundred forty patients who underwent PCI in this investigation. They discovered that increased use of prasugrel and ticagrelor was accompanied by increased nonfilling of prescriptions for P2Y₁₂ inhibitors within 30 days of discharge between 2008 and 2016. Compared with clopidogrel, prasugrel and ticagrelor had higher patient costs and lower adherence in the year following PCI. Data reported that the introduction of newer, more expensive P2Y₁₂ inhibitors was associated with lower adherence to these therapies.